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METHODS 6 
Study populations 7 
The present project includes nine independent studies (Table E1) among which five 8 
population-based studies: the European Community Respiratory Health Survey (ECRHS), the 9 
Swiss study on Air Pollution and Lung and Heart Disease In Adults (SAPALDIA), the 10 
Busselton Health Study (BUSSELTON), the GABRIEL Advanced Surveys (GABRIELA) 11 
and the UFA study (UFA); three familial studies: the Epidemiological study on the Genetics 12 
and Environment of Asthma (EGEA); the Saguenay-Lac-Saint-Jean Familial Collection 13 
(SLSJ) and the TOMSK study (TOMSK); and one birth cohort: the Avon Longitudinal Study 14 
of Parents and Children (ALSPAC). All of these studies were part of the GABRIEL European 15 
consortium on asthma,1 and had the information on age of asthma onset, age at last 16 
examination and imputed genetic data available. A total of 13,886 subjects from European 17 
ancestry were included in the time-to-asthma onset GWAS meta-analysis (5,462 asthmatics 18 
and 8,424 non-asthmatics).  19 
 20 
Study populations and Phenotype definition 21 
ALSPAC 22 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a population‐based birth 23 
cohort initially comprising of 14,541 mothers and their children recruited in the former 24 
County of Avon, UK between 1991 and 1992.2 25 
2 
Asthmatics were defined by a positive response to the question: “Did you child had asthma in 26 
past 12 months?” at 81, 91, 103, 128, 157 or 166 months. Non-asthmatics were those who 27 
answered no at all surveys. In asthmatics, age of onset was defined by the first time they 28 
declared wheeze or wheezing and whistling. Wheeze was defined by a positive response to 29 
the question: “Has your child had wheezing, breathlessness or episodes of stopping breathing 30 
in past 12 months or since he was (age at last Q)?”. Wheezing and whistling were defined by 31 
a positive response to the question: “Has your child had any periods when there was wheezing 32 
with whistling on his chest when he breathed in past 12 months or since he was (age at last 33 
Q)?”. In non-asthmatics, we considered age at the last examination without any missing visit 34 
at the preceding surveys. Thus, for non-asthmatics with negative complete reports, we 35 
considered age at last examination and for non-asthmatics with negative incomplete and/or 36 
discontinued reports, we considered age until the last visit before the first missing visit. We 37 
did not include in the present analysis non-asthmatics who experienced wheeze or wheezing 38 
and whistling before 6yrs of age. 39 
 40 
ECRHS 41 
The ECRHS study is a European population-based study of young adults with a 8-year 42 
follow-up (ECRHS I: 1991-1993, ECRHS II: 1999-2002 and ECRHS III: 2010-ongoing).3,4 43 
The time-to-asthma onset GWAS is based on the two first survey data. Participants included 44 
in the meta-analysis were derived from the nested asthma case/control sample subjected to 45 
genome-wide genotyping in the context of the GABRIEL asthma GWAS. 46 
Asthma cases were identified by participants from the random or enriched sample who said 47 
yes to the question ‘Have you ever had asthma?’ at either ECRHS I Stage 2 or at ECRHS II. 48 
Controls were a random sample (of the random sample) who answered ‘no’ to the same 49 
question in both surveys. For individuals who developed asthma, information on asthma age 50 
3 
at onset was obtained from age at first asthma attack at ECRHS I or II. For individuals who 51 
were free of disease upon examination, we considered age at last examination. 52 
 53 
EGEA 54 
Briefly, the EGEA study combines a case-control and a family-based study of asthma cases 55 
(N=2,120 subjects) with three surveys over 20 years (EGEA1: 1991-1995, EGEA2: 2003-56 
2007 and EGEA3: 2011-2013). The whole study population included 388 asthmatic probands 57 
recruited in chest clinics and their 1,317 family members (probands’ parents and/or siblings) 58 
plus 415 population-based controls.5 59 
Asthma was defined in probands by a positive answer to the following four items “Have you 60 
ever had attacks of breathlessness at rest with wheezing?”, “Have you ever had asthma 61 
attacks?”, “Was this diagnosis confirmed by a physician?”, and “Have you had an asthma 62 
attack in the last 12 months?” or on a positive self-report to two of the before mentioned items 63 
plus a medical record of asthma. Individuals were considered free of disease if they answered 64 
no at all items. Relatives of probands were defined as asthmatics if they answered positively 65 
at either survey to “Have you ever had attacks of breathlessness at rest with wheezing?” or 66 
“Have you ever had asthma attacks?” at EGEA1, EGEA2 or EGEA3.  67 
For individuals who developed asthma, information on asthma age at onset was obtained from 68 
adult asthmatics or parents of asthmatic children who answered to the following question: 69 
“How old were you when you had your first asthma attack?” or “How old was your child 70 
when he (or she) had his (her) first asthma attack?”. For individuals who were free of disease 71 
upon last examination, we considered age at last examination. 72 
 73 
 74 
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GABRIEL Advanced Surveys  76 
GABRIELA are cross-sectional population-based surveys conducted in rural areas of Austria, 77 
Germany, and Switzerland during fall/winter 2006 and spring/summer 2007.6 78 
A case was defined as a parental report of asthma diagnosed by a doctor at least once or 79 
asthmatic bronchitis diagnosed at least twice during lifetime. The reference category for 80 
asthma was no reported diagnosis of asthma ever and a diagnosis of asthmatic bronchitis no 81 
more than once. The original question on age of onset was: “How old was your child when 82 
the first symptoms of wheezing or whistling in the chest began? At the age of … years. If 83 
during the first year: At the age of … months.” The variable is coded for years. Months were 84 
transferred to years. In non-asthmatics, we considered age at examination. To define atopy, 85 
we used an atopic sensitization to mite, cat, or birch upper or equal to 0.7 kU/L. 86 
 87 
SAPALDIA  88 
The SAPALDIA study is a cohort study with integrated biobank in the Swiss population 89 
initiated in 1991 (SAPALDIA 1: n=9,651; age 18-60 at baseline) with two follow-up 90 
assessments in 2001-2003 (SAPALDIA 2: n=8,047) and in 2010-2011 (SAPALDIA 3: 91 
n=6,200).7,8 The time-to-asthma onset GWAS is based on the first two survey data. 92 
Participants included in the meta-analysis were derived from the nested asthma case/control 93 
sample subjected to genome-wide genotyping in the context of the GABRIEL asthma GWAS. 94 
Asthma status was defined by an affirmative answer to the question “Have you ever had 95 
asthma” at baseline and/or follow-up interview. Controls were defined by a negative answer 96 
to the same question. Age of onset was self-reported by study participants. For individuals 97 
who were free of disease upon examination, we considered age at last examination. 98 
 99 
 100 
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BUSSELTON 101 
The Busselton Health Study is a population-based, nested, case-control panel of 1,549 102 
individuals of European Caucasian descent from Australia9,10 with seven cross-sectional 103 
respiratory health surveys of adults conducted between 1966 and 2005-2007 and five cross-104 
sectional respiratory health surveys of all school children conducted between 1967 and 1983. 105 
Asthma cases were defined as those who reported doctor-diagnosed asthma at any survey that 106 
they attended from 1966 to 1994 (answer ‘Yes’ to ‘Has your doctor ever told you that you had 107 
asthma?’). Controls are those who have consistently answered ‘No’ to ‘Has your doctor ever 108 
told you that you had asthma?’ at all previous surveys that they have attended from 1966 to 109 
1994. Age of onset was obtained from answer to the following question “How old were you 110 
when you first developed symptoms of asthma?”. For individuals who were free of disease 111 
upon examination, we considered age at last examination. 112 
 113 
SLSJ 114 
The Saguenay-Lac-Saint-Jean and Quebec City Familial Asthma Collection (SLSJ) consisting 115 
of a French-Canadian founder population panel of 253 multigenerational families from 116 
Saguenay-Lac-Saint-Jean region, ascertained through two asthmatic probands between 1997 117 
and 2002.11 118 
Probands were included in the study if they fulfill at least two of the following criteria: 1) a 119 
minimum of three clinic visits for acute asthma within one year; 2) two or more asthma-120 
related hospital admissions within one year; or 3) steroid dependency, as defined by either six 121 
months of oral, or one year of inhaled corticosteroid use. Families were included in the study 122 
if at least one parent was available for phenotypic assessment, at least one parent was 123 
unaffected, and all four grandparents were of French-Canadian origin. For family members, 124 
they were considered as asthmatic: (1) if they had a reported history of asthma (validated by a 125 
6 
physician), or (2) if they presented asthma-related symptoms and positive PC20 (less or equal 126 
to 8mg/ml of methacholine) at recruitment. If individuals had at least one positive response on 127 
skin prick tests (wheal diameter X 3mm at 10min), they were defined as atopic. Age of onset 128 
was obtained from answers to the following questions “Have you ever had asthma attacks? 129 
How old were you when you had your first asthma attack?”. When age of onset was defined 130 
below 2 years (in 41 cases), a default class of 2 years was adopted to avoid uncertainty. For 131 
non-asthmatics, we considered the age at examination. 132 
 133 
UFA 134 
UFA is a population-based case-control study of asthma cases and controls matched on age 135 
and sex and recruited between 1999 and the year 2007.12 Subjects are of different ethnic 136 
origins (Russians, Tatars and Bashkirs) from Volga-Ural region of Russian Federation. 137 
Cases are unrelated patients with physician-diagnosed asthma and controls are free of disease. 138 
Asthma patients were diagnosed by pulmonologists on the basis of clinical examination, 139 
family and medication history, objective tests of lung function. The controls were healthy 140 
subjects who met all the following criteria: (1) no symptoms or history of asthma or other 141 
pulmonary diseases; (2) no symptoms or history of atopy; and (3) absence of first-degree 142 
relatives with a history of asthma or atopy. The age of asthma onset was obtained from 143 
answer to the following question “How old were you when you had your first attack of 144 
asthma?”. For non-asthmatics, we considered the age at examination. 145 
 146 
TOMSK 147 
TOMSK is a population-based family study conducted by the Research Institute of Medical 148 
Genetics and Siberian State Medical University (TOMSK, Russia) from 1998 onwards.13,14 149 
7 
Both nuclear families and extended pedigrees were recruited through atopic bronchial 150 
asthmatic probands. Both probands and their relatives were clinically examined to establish 151 
diagnosis of asthma and atopy using the GINA criteria (Global Initiative for Asthma: Global 152 
Strategy for Asthma Management and Prevention. http://www.ginasthma.org).  The age of 153 
onset was set as the age when asthma was first diagnosed by a doctor. For newly identified 154 
cases, it was established through their physical examination, while for other cases, it was 155 
established through the reply to a question: “What age were you when doctor first time told 156 
you that you have asthma?”. For non-asthmatics, we considered the age at examination. 157 
 158 
eQTL analysis and functional annotations 159 
We assessed whether significant SNPs associated with time-to-asthma onset (or their proxies) 160 
were expression quantitative trait loci (eQTLs) by using publically available databases: eQTL 161 
Browser (lymphoblastoid cell lines (LCLs) from British asthma (MRCA) and eczema 162 
(MRCE) family subjects),15 Blood eQTL Browser (non-transformed peripheral blood 163 
samples),16 Lung eQTLs (lung tissue),17 GTEx eQTL Browser release v4 (uploaded in July 164 
2015 for multiple tissues including blood and lung)18 and eQTL Chicago Browser that 165 
includes eQTL results from many sources among which Montgomery et al,19 Stranger et al20 166 
and Veyrieras et al21 that were performed in human LCLs. 167 
 168 
Replication of prior asthma GWAS results  169 
Finally, we evaluated whether previously reported susceptibility loci for asthma and asthma-170 
related phenotypes (asthma exacerbation, asthma-plus-rhinitis comorbidity, age of asthma 171 
onset and bronchial-hyper-responsiveness) at genome-wide significance level were associated 172 
with time-to-asthma onset in our meta-analysis using data from the NHGRI Catalog of 173 
Published GWASs (last update June 2015).22 A total of 15 GWASs mainly conducted on 174 
8 
European populations have reported 57 SNPs belonging to 28 independent loci (including 175 
seven loci specific to Japanese subjects or African-Americans and Latinos) associated with 176 
asthma and/or selected asthma-related phenotypes at a genome-wide significant level. 177 
 178 
RESULTS 179 
Functional annotations and effect on gene expression of main time-to-asthma onset 180 
associated SNPs 181 
To provide some insights into the potential molecular mechanisms underlying the TAO 182 
associated variants, we queried whether the seven top SNPs (or their proxies) were 1) tagging 183 
potentially deleterious SNPs, 2) located in regulatory elements, and 3) reported to influence 184 
the expression of one or more of nearby genes (eQTLs at P<5x10−5; see Table III and Table 185 
E3 for summary and complete results respectively).  186 
The 2q12 region top SNP (rs10208293) is located within interleukin 1 receptor-like 1 gene 187 
(IL1RL1) in a binding site of the nuclear factor-κB (NFkB1) and is in strong LD (D’=1 and 188 
r²=0.57) with three IL1RL1 missense SNPs (rs4988956, rs10192157 and rs10206753). This 189 
SNP and one of its proxy correlate with the expression of interleukin 18 receptor 1 (IL18R1) 190 
and IL18 receptor accessory protein (IL18RAP) genes in blood.16 191 
In 6p21 region, the strongest association was with rs9272346 located near HLA-DQA1. This 192 
SNP lies within an enhancer histone mark in B cells and is in strong LD (r²>0.8) with SNPs in 193 
a predicted promoter in B cells. This SNP (or its proxies) correlates with the expression of 17 194 
HLA class II genes in blood tissue and lymphoblastoid cell lines (LCL).15,16,18-20 However, 195 
due to the extensive LD within HLA region, some of these associations might reflect signal 196 
inter-correlations rather than true pleiotropic effects on gene expression. 197 
9 
The two distinct SNPs (rs928413 and rs413382) associated with TAO at 9p24 are located in 198 
intergenic region upstream of IL33. We did not find any evidence for eQTL for these SNPs or 199 
their proxies. 200 
The span of the SNPs associated with TAO at genome-wide significance level in 17q12-q21 201 
region was approximately 389 kb. The strongest association was with a SNP (rs9901146) 202 
nearby zona pellucida binding protein 2 gene (ZPBP2) that is in strong LD with several SNPs 203 
tagging and/or belonging to other genes in the region: IKAROS family zinc finger 3 (IKZF3), 204 
ZPBP2 (including rs11557467 missense SNP), gasdermin B (GSDMB; among which two 205 
missense SNPs rs2305480 and rs2305479) and ORMDL sphingolipid biosynthesis regulator 3 206 
(ORMDL3). The rs9901146-G risk allele was positively correlated with the expression of 207 
GSDMB and ORMDL3, and negatively with IKZF3 expression in LCL and blood 208 
tissue.15,16,18,19,21 The second distinct signal at 17q12-q21 (rs3859192) is located within the 209 
gasdermin A gene (GSDMA), in a GABPA (GA binding protein transcription factor, alpha 210 
subunit) binding site. Moreover, this SNP is in strong LD with  rs56030650 missense SNP 211 
(GSDMA) and SNPs lying in a predicted promoter in B cells. The rs3859192-T risk allele was 212 
correlated with decreased expression of GSDMA in the lung17 and increased expression of 213 
both GSDMB and ORMDL3 in LCLs.15  214 
 215 
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Table E1. Main characteristics of the nine studies included in the meta-analysis of time-to-asthma onset GWAS  325 
 ALSPAC BUSSELTON ECRHS EGEA GABRIELA SAPALDIA SLSJ TOMSK UFA 
Cohort information          
Country United-Kingdom Australia Europe France Austria, Germany, Switzerland Switzerland Canada Russia Russia 
Study collection type Birth Cohort Population-based Case/Control 
Population-based 
case-control study 
Longitudinal 
Case/Control and 
Family study 
Population-based 
Case/Control 
Population-based 
case-control study
Population-
based family 
study 
Population-based 
family study 
Population-
based case-
control study 
Sample Size          
 3,420 1,191 2,085 1,835 1,503 1,435 1,127 622 669 
Main characteristics          
Sex, men (%) 1,760 (51.5) 510 (42.8) 981 (47.1) 937 (51.1) 849 (56.5) 698 (48.6) 515 (45.7) 341 (54.8) 413 (61.7) 
Age in years*, mean 
(SD) 13.9 (0.1) 53.4 (17.3) 42.8 (7.1) 31.3 (17.0) 9.0 (1.6) 52.3 (11.2) 38.4 (21.6) 27.2 (16.7) 19.2 (13.3) 
Asthma, n (%) 1,336 (39.1) 391 (32.8) 618 (29.7) 793 (43.2) 664 (44.2) 557 (38.8) 534 (47.4) 240 (38.6) 329 (49.2) 
Asthma age-of-onset, 
median [25-75%] 1.6 [0.5-5.6] 18 [6-35] 20 [7-30] 9 [3-25] 2 [0.8-4] 21 [7-37] 9 [3-25] 5 [3-12] 5 [2-13] 
Atopy**, n (%) 652 (25.1) 507 (42.6) 864 (41.5) 1,063 (57.9) 812 (54.0)  - 618 (54.8) 381 (61.3) 281 (42.0)*** 
IgE (UI/mL), mean (SD) 267.4 (555.6) NA 135.9 (296.9) 282.6 (632.4) NA 119.8 (263.8) 182.8 (202.8) 226.3 (261.4) 238.7 (373.5) 
Genotyping          
Genotyping platform 
and SNP panel 
Illumina 
HumanHap550Quad Illumina 610K Illumina 610K Illumina 610K Illumina 610K Illumina 610K Illumina 610K Illumina 610K Illumina 610K 
16 
 ALSPAC BUSSELTON ECRHS EGEA GABRIELA SAPALDIA SLSJ TOMSK UFA 
Genotyping center 
23andMe 
subcontracting the 
Wellcome Trust 
Sanger Institute, 
Cambridge, UK, and 
the LabCorp, 
Burlington, North 
Carolina, US 
Centre National de 
Génotypage, Evry, 
France 
Centre National de 
Génotypage, Evry, 
France 
Centre National de 
Génotypage, Evry, 
France 
Centre National de 
Génotypage, Evry, 
France 
Centre National de 
Génotypage, Evry, 
France 
Centre National 
de Génotypage, 
Evry, France 
Centre National de 
Génotypage, Evry, 
France 
Centre 
National de 
Génotypage, 
Evry, France 
Individual QC          
Call-rate 97% 97% 97% 97% 97% 97% 97% 97% 97% 
Heterozygosity 
Individuals excluded if 
<0.320 or >0.345 for 
the Sanger data and 
<0.310 or >0.330 for 
the LabCorp data 
Individuals excluded 
if <0.30 or >0.33 
Individuals excluded 
if <0.30 or >0.33 
Individuals 
excluded if <0.30 
or >0.33 
Individuals excluded if 
<0.30 or >0.33 
Individuals 
excluded if <0.30 
or >0.33 
Individuals 
excluded if 
<0.30 or >0.33
Individuals 
excluded if <0.30 
or >0.33 
Individuals 
excluded if 
<0.30 or >0.33 
Ethnic outliers PCA based PCA based PCA based PCA based PCA based PCA based PCA based PCA based PCA based 
SNP QC filters before 
imputation          
MAF 1% 5% 5% 5% 5% 5% 5% 5% 5% 
HWE p-value 5x10-7 10-4 10-4 10-4 10-4 10-4 10-4 10-4 10-4 
Call-rate 95% 97% 97% 97% 97% 97% 97% 97% 97% 
Imputation - Genome          
Software MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 MACH 1.0 
Hapmap release Hapmap2 r22 Hapmap2 r21 Hapmap2 r21 Hapmap2 r21 Hapmap2 r21 Hapmap2 r21 Hapmap2 r21 Hapmap2 r24 Hapmap2 r21 
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 ALSPAC BUSSELTON ECRHS EGEA GABRIELA SAPALDIA SLSJ TOMSK UFA 
SNP QC filters Rsq ≥ 0.5 & MAF ≥ 1% 
Rsq ≥ 0.5 & MAF ≥ 
1% 
Rsq ≥ 0.5 & MAF ≥ 
1% 
Rsq ≥ 0.5 & MAF 
≥ 1% 
Rsq ≥ 0.5 & MAF ≥ 
1% 
Rsq ≥ 0.5 & MAF 
≥ 1% 
Rsq ≥ 0.5 & 
MAF ≥ 1% 
Rsq ≥ 0.5 & MAF 
≥ 1% 
Rsq ≥ 0.5 & 
MAF ≥ 1% 
Imputation - Region          
Software MINIMAC IMPUTE2 v2.1.2  IMPUTE2 v2.1.2  IMPUTE2 v2.1.2 IMPUTE2 v2.1.2  IMPUTE2 v2.1.2 IMPUTE2 v2.1.2  IMPUTE2 v2.1.2 
IMPUTE2 
v2.1.2 
1000G release November 2010 June 2014 June 2014 June 2014 June 2014 June 2014 June 2014 June 2014 June 2014 
SNP QC filters Rsq ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 Info ≥ 0.5 
*Age at last examination 326 
**Atopy defined by a positive skin prick test response to at least one aeroallergen 327 
***Available only in asthmatics 328 
18 
Table E2. Results of the analyses conducted in 16q12 region using 1000G CEU reference 329 
sample. 330 
 331 
Marker Position* Alleles Effect/Ref† 
Effect 
Freq 
Hazard Ratio 
[95% CI] 
P-value‡ P-Het** 
rs11867101 50 847 368 T/C 0.03 1.32 [1.19-1.45] 1.1x10-7 0.16 
rs11863019 50 847 819 C/A 0.04 1.32 [1.19-1.47] 6.3x10-8 0.12 
rs4785228 50 848 914 A/G 0.03 1.32 [1.19-1.47] 1.4x10-7 0.17 
rs7199870 50 850 082 T/C 0.03 1.32 [1.19-1.47] 9.2x10-8 0.13 
rs2032688 50 850 847 T/C 0.03 1.32 [1.19-1.47] 5.8x10-8 0.14 
rs7195092 50 852 366 G/C 0.03 1.32 [1.19-1.47] 3.8x10-8 0.11 
rs2032687 50 852 432 T/C 0.03 1.32 [1.19-1.47] 1.2x10-7 0.11 
rs4785458 50 856 194 A/G 0.03 1.32 [1.19-1.47] 6.2x10-8 0.10 
rs1861760 50 857 693 A/C 0.04 1.28 [1.16-1.41] 2.6x10-7 0.10 
 332 
*Position in base pairs (bp) – build 37.3 NCBI. 333 
†For the calculation of the hazard ratios, effect alleles (Effect) were designated as risk alleles. Effect Freq 334 
denotes effect allele frequency, CI confidence interval, and Ref reference allele. 335 
‡P-values are obtained from meta-analysis of single-SNP Cox model of time-to-asthma onset adjusted for sex 336 
and principal components. 337 
**P-Het value reflect test of heterogeneity across studies using Cochran’s Q test. 338 
 339 
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Table E3. Cis-eQTLs results for the top SNPs (and their proxies) in genome-wide associated regions from the meta-analysis of time-to-asthma 340 
onset. We focused our search on eQTLs measured in blood, LCLs and lung tissue. 341 
Chr SNP Position 
(build 37.3) 
LD (D’/r²) 
with main SNP 
Alleles† 
(Ref/Effect) 
Z score / 
LOD 
P-value Gene FDR Source Tissue Reference 
2 rs10208293* 102 966 310 - G/A 34.06 9.8x10-198 IL18RAP <10-5 Blood eQTLs Blood Westra et al, 2013 
    G/A 11.65 2.5x10-13 IL18R1 NA eQTL Browser LCLs (eczema) Liang et al, 2013 
  rs3771167 102 986 188 rs10208293 
(D'=1, r²=0.56) 
G/A 7.34 2.1x10-13 IL18R1 <10-5 Blood eQTLs Blood Westra et al, 2013 
                       
6 rs9272346* 32 604 372 - NA NA 2.1x10-21 HLA-DQA1 NA eQTL_Chicago LCLs Stranger et al, 2007 
        NA NA 4.6x10-21 HLA-DQA1 NA eQTL_Chicago LCLs Montgomery et al, 2010 
        NA NA 8.3x10-18 HLA-DQB1 NA eQTL_Chicago LCLs Montgomery et al, 2010 
        NA NA 1.1x10-7 HLA-DRB1 NA eQTL_Chicago LCLs Montgomery et al, 2010 
        G/A -10.61 1.4x10-26 HLA-DQA1 NA GTEx Lung GTEx consortium, 2013 
        G/A -12.57 1.6x10-36 HLA-DQA1 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A 8.98 1.4x10-19 HLA-DQA2 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A 6.63 1.7x10-11 HLA-DQA2 NA GTEx Lung GTEx consortium, 2013 
        G/A -8.84 4.6x10-19 HLA-DQB1 NA GTEx Lung GTEx consortium, 2013 
        G/A -12.16 2.4x10-34 HLA-DQB1 NA GTEx Whole_Blood GTEx consortium, 2013 
20 
Chr SNP Position 
(build 37.3) 
LD (D’/r²) 
with main SNP 
Alleles† 
(Ref/Effect) 
Z score / 
LOD 
P-value Gene FDR Source Tissue Reference 
        G/A -8.72 1.4x10-18 HLA-DQB1-
AS1 
NA GTEx Lung GTEx consortium, 2013 
        G/A -11.34 4x10-30 HLA-DQB1-
AS1 
NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A 10.06 4x10-24 HLA-DQB2 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A -6.85 7.5x10-12 HLA-DRA <10-5 Blood eQTLs Blood Westra et al, 2013 
        G/A -5.85 2.5x10-9 HLA-DRB1 NA GTEx Lung GTEx consortium, 2013 
        G/A -7.43 5.3x10-14 HLA-DRB1 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A -23.43 2.1x10-121 HLA-DRB5 <10-5 Blood eQTLs Blood Westra et al, 2013 
        G/A -5.15 1.3x10-7 HLA-DRB5 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A 4.70 1.3x10-6 HLA-DRB6 NA GTEx Whole_Blood GTEx consortium, 2013 
        G/A -6.60 4.1x10-11 TAP2 <10-5 Blood eQTLs Blood Westra et al, 2013 
  rs3129889 32 413 545 rs9272346 
(D'=1, r²=0.41) 
G/A -6.68 2.9x10-8 HLA-DRB1 NA eQTL Browser LCLs (asthma) Liang et al, 2013 
  rs9272723 32 609 427 rs9272346 
(D'=1, r²=0.97) 
T/C -10.10 5.7x10-24 TAP2 <10-5 Blood eQTLs Blood Westra et al, 2013 
7.23 4.8x10-13 HLA-DOB <10-5 
-25.04 2.3x10-138 HLA-DRB5 <10-5 
21 
Chr SNP Position 
(build 37.3) 
LD (D’/r²) 
with main SNP 
Alleles† 
(Ref/Effect) 
Z score / 
LOD 
P-value Gene FDR Source Tissue Reference 
  rs9273325 32 623 193 rs9272346 
(D'=1, r²=0.02) 
A/G -4.50 6.9x10-6 TAP1 NA eQTLs_Lung Lung Hao et al, 2012 
  rs2859579 32 784 073 rs9272346 
(D'=1, r²=0.007) 
T/G 19.10 6.8x10-21 TAP2 NA eQTL Browser LCLs (asthma) Liang et al, 2013 
  rs9277725 33 091 543 rs9272346 
(D'=1, r²=0.05) 
T/A 15.60 2.3x10-17 HLA-DPB2 NA eQTL Browser LCLs (asthma) Liang et al, 2013 
  rs2395357 33 101 006 rs9272346 
(D'=1, r²=0.05) 
A/G 7.80 6.2x10-15 HSD17B8 <10-5 Blood eQTLs Blood Westra et al, 2013 
-6.66 2.8x10-11 HLA-DPB1 <10-5 
-5.12 3.1x10-7 HLA-DMA 10-4 
                       
16 rs1861760* 50 857 693 - C/A 6.62 3.6x10-11 NOD2 <10-5 Blood eQTLs Blood Westra et al, 2013 
  rs5743266 
(now rs2076752) 
50 731 096 rs1861760 
(D'=1, r²=0.02) 
A/G -5.85 5.0x10-9 CYLD <10-5 Blood eQTLs Blood Westra et al, 2013 
23.31 3.2x10-120 NOD2 <10-5 
  rs7205760 50 844 773 rs1861760 
(D'=1, r²=0.005) 
C/G 4.69 2.8x10-6 CYLD NA eQTLs_Lung Lung Hao et al, 2012 
7.85 4.0x10-15 NOD2 <10-5 Blood eQTLs Blood Westra et al, 2013 
                       
17 rs9901146* 38 043 343 - A/G 36.54 9.8x10-198 GSDMB <10-5 Blood eQTLs Blood Westra et al, 2013 
22 
Chr SNP Position 
(build 37.3) 
LD (D’/r²) 
with main SNP 
Alleles† 
(Ref/Effect) 
Z score / 
LOD 
P-value Gene FDR Source Tissue Reference 
        A/G 6.00 9.9x10-10 GSDMB NA GTEx Whole_Blood GTEx consortium, 2013 
        A/G 8.55 1.3x10-17 GSDMB NA eQTL Browser LCLs (asthma) Liang et al, 2013 
    A/G 33.50 2.2x10-35 GSDMB NA eQTL Browser LCLs (eczema) Liang et al, 2013 
        A/G 36.41 9.8x10-198 ORMDL3 <10-5 Blood eQTLs Blood Westra et al, 2013 
        A/G 11.16 6.2x10-29 ORMDL3 NA eQTL Browser LCLs (asthma) Liang et al, 2013 
    A/G 42.30 3.3x10-44 ORMDL3 NA eQTL Browser LCLs (eczema) Liang et al, 2013 
        NA NA 1.3x10-10 ORMDL3 NA eQTL_Chicago LCLs Veyrieras et al, 2008 
        NA NA 3.8x10-6 ORMDL3 NA eQTL_Chicago LCLs Montgomery  et al, 2010 
        A/G 4.57 2.4x10-6 ORMDL3 NA GTEx Whole_Blood GTEx consortium, 2013 
  rs9896940 37 895 975 rs9901146 
(D'=1, r²=0.07) 
G/A -15.81 2.6x10-56 IKZF3 <10-5 Blood eQTLs Blood Westra et al, 2013 
                       
17 rs3859192* 38 128 648 - C/T -6.91 2.5x10-12 GSDMA NA GTEx Lung GTEx consortium, 2013 
    C/T 6.10 1.1x10-7 GSDMB NA eQTL Browser LCLs (eczema) Liang et al, 2013 
    C/T 8.10 1.1x10-9 ORMDL3 NA eQTL Browser LCLs (eczema) Liang et al, 2013 
*Top Genome-wide significant SNPs in time-to-asthma onset meta-analysis and secondary associations identified by conditional analyses are indicated in bold 342 
†Haplotype reconstruction was done using Haploview.23 The effect allele of the top SNP is always transmitted with the indicated effect allele of its proxy 343 
23 
Table E4. Comparison of the main results of time-to-asthma onset (TAO, in bold) GWAS meta-analysis (P≤5x10-8) with asthma (binary trait) 344 
GWAS meta-analysis results obtained in the same nine studies and in the whole GABRIEL dataset (25 studies, N=26,475)1 345 
      TAO meta-analysis9 studies 
AST (binary) meta-analysis 
9 studies AST (binary) meta-analysis All GABRIEL ALL Childhood-onset Adult-onset 
P HetChr Marker Position* Closest Gene(kb distance)
Effect 
allele 
Freq 
Effect/ 
Ref 
Alleles† 
HR P‡ Phet** OR fix P fix ORran P ran Phet
OR 
fix P fix 
OR 
ran P ran Phet OR fix P fix 
OR 
ran P ran P het OR P ran P fix P het 
2 rs10208293 102.97 IL1RL1 0.27 A/G 0.88 3.1x10-8 0.26 0.88 4.0x10-5 0.88 4.7x10-3 0.03 0.84 1.4x10-5 0.84 1.4x10-5 0.84 0.94 2.7x10-1 0.97 7.8x10-1 0.004 0.07 
2 rs3771166 102.99 IL18R1 0.38 A/G 0.89 5.0x10-8 0.57 0.88 5.5x10-6 0.88 4.2x10-4 0.10 0.84 6.0x10-7 0.84 6.0x10-7 0.53 0.96 3.4x10-1 0.97 6.1x10-1 0.13 0.02 1.15 3.4x10-9 3.5x10-12 0.18 
6 rs9272346†† 32.60 HLA-DQA1 (0.8) 0.58 A/G 1.13 1.6x10-8 0.12 1.17 4.9x10-8 1.17 1.2x10-7 0.38 1.13 6.1x10-4 1.14 2.5x10-3 0.21 1.25 6.3x10-6 1.25 6.3x10-6 0.83 0.12 1.18 7.0x10-14 7.0x10-14 0.50 
9 rs413382 6.14 IL33 (73) 0.80 A/C 1.16 5.9x10-8 0.84 1.20 3.3x10-7 1.22 1.9x10-4 0.01 1.19 2.2x10-4 1.19 5.8x10-3 0.06 1.23 3.7x10-4 1.26 1.8x10-2 0.02 0.63 
9 rs1342326 6.19 IL33 (26) 0.84 A/C 0.84 1.6x10-12 0.43 0.80 2.1x10-9 0.80 6.9x10-6 0.05 0.74 4.8x10-11 0.73 7.1x10-9 0.26 0.93 1.9x10-1 0.92 1.9x10-1 0.41 0.003 1.20 9.2x10-10 8.7x10-12 0.22 
9 rs928413 6.21 IL33 (2) 0.76 A/G 0.84 6.5x10-16 0.15 0.80 2.2x10-12 0.80 2.5x10-7 0.04 0.75 5.4x10-13 0.75 4.7x10-9 0.16 0.90 3.0x10-2 0.90 4.7x10-2 0.33 0.006 
15 rs744910 6.74 SMAD3 0.51 A/G 0.93 3.2x10-4 0.60 0.92 1.9x10-3 0.92 1.9x10-3 0.87 0.90 2.0x10-3 0.90 2.0x10-3 0.81 0.95 2.9x10-1 0.95 2.9x10-1 0.74 0.31 1.12 3.9x10-9 3.9x10-9 0.85 
16 rs1861760 50.86 CYLD (22) 0.04 A/C 1.28 4.2x10-8 0.11 1.36 3.8x10-6 1.37 3.3x10-5 0.22 1.35 3.8x10-4 1.36 1.1x10-2 0.05 1.37 3.1x10-3 1.37 3.1x10-3 0.79 0.93 
17 rs9901146 38.04 ZPBP2 (9) 0.48 A/G 0.85 1.9x10-16 0.17 0.85 4.0x10-9 0.85 7.3x10-5 0.01 0.78 3.0x10-12 0.78 3.0x10-12 0.61 0.98 5.9x10-1 0.96 5.4x10-1 0.15 0.0002
17 rs2305480 38.06 GSDMB 0.42 A/G 0.85 8.1x10-16 0.14 0.85 1.7x10-8 0.86 3.7x10-4 0.004 0.77 4.1x10-13 0.77 4.1x10-13 0.83 1.01 8.3x10-1 1.00 9.7x10-1 0.20 4.9x10-6 1.18 9.6x10-8 - 0.0009 
17 rs3894194 38.12 GSDMA 0.47 A/G 1.16 1.4x10-13 0.89 1.17 1.7x10-8 1.17 1.4x10-6 0.19 1.25 8.6x10-11 1.25 8.6x10-11 0.88 1.04 4.3x10-1 1.04 4.3x10-1 0.55 9.3x10-4 1.17 4.6x10-9 - 0.02 
17 rs3859192 38.13 GSDMA 0.54 C/T 0.86 1.5x10-13 0.90 0.86 2.7x10-8 0.86 2.7x10-8 0.64 0.81 1.7x10-9 0.81 1.7x10-9 0.95 0.95 2.2x10-1 0.95 2.2x10-1 0.82 0.009 
22 rs2284033 37.53 IL2RB 0.47 A/G 0.94 2.1x10-3 0.36 0.91 1.1x10-3 0.91 1.1x10-3 0.66 0.94 7.9x10-2 0.94 7.9x10-2 0.46 0.87 2.0x10-3 0.87 2.0x10-3 0.86 0.16 1.12 1.2x10-8 1.2x10-8 0.92 
LD between TAO main SNPs and GABRIEL main SNPs in genome-wide associated regions: 346 
2q12: rs10208293 & rs3771166 (r²=0.53, D'=0.95); 6p21: rs9272346 & rs9273349 (r²=D'=1.0); 9p24: rs928413 & rs1342326 (r²=0.51, D'=1.0), rs413382 - rs1342326 (r²=0.0, 347 
D'=0.23); 17q12-21: rs9901146 & rs2305480 (r²=0.82, D'=1.0), rs3859192 & rs3894194 (r²=0.43, D'=0.71) 348 
*Position in megabases (Mb) – build 37.3 NCBI 349 
†For the calculation of the hazard ratios, effect alleles were designated as risk alleles. Effect Freq denotes frequency of the effect allele, CI confidence interval, and Ref 350 
reference allele. 351 
24 
‡P-value obtained from single-SNP Cox model for time-to-asthma onset adjusted for sex and principal components (fixed-effect model when there was no significant evidence 352 
of heterogeneity or random-effect model otherwise) 353 
**P-Het reflects P-value of Cochran’s Q statistic across studies 354 
†† main GABRIEL SNP in 6p21 (rs9273349) was not imputable 355 
‡‡ Additional distinct SNPs detected with conditional analyses 356 
25 
Table E5. Published genome-wide associations with asthma compared with time-to-asthma onset GWAS meta-analysis results 357 
    Meta-analysis of time-to-asthma onset 
GWASs 
GW results reported in GWAS for asthma and asthma-related traits 
NCBI GWAS Catalog, June 2015 
Chr SNP 
or proxy* 
Pos  
(Mb) 
Gene 
Symbol 
Effect/Ref 
Alleles† 
Effect 
Freq 
HR 
[95% CI] 
P‡ Mapped 
Genes 
Effect 
Allele 
Effect 
Freq 
in ctrls 
P OR 
[95% CI] 
Trait References Pop 
1 rs4129267 154.43 IL6R C/T 0.57 0.97 
[0.94-1.01] 
0.19 IL6R T 0.37 2.0x10-8 1.09 
[1.06-1.12] 
Asthma Ferreira, Lancet, 
201124 
European 
1 rs1101999 158.93 PYHIN1 NA NA NA NA PYHIN1 NA NA 4.0x10-9 NA Asthma Torgerson, Nat Genet, 
201125 
African 
American & 
Latinos 
1 rs2786098 197.33 CRB1 G/T 0.78 1.03 
[0.98-1.08] 
0.25 CRB1-DENND1B NA 0.85 2.0x10-13 1.43 
[NA] 
Asthma Sleiman, N Engl J 
Med, 201026 
European 
2 rs3771180 102.95 IL1RL1 G/T 0.86 1.16 
[1.1-1.23] 
5.9x10-7 IL1RL1 NA NA 2.0x10-15 NA Asthma Torgerson, Nat Genet, 
201125 
Multi-ethnic 
2 rs13408661 102.96 IL1RL1 A/G 0.14 0.86 
[0.81-0.91] 
5.9x10-7 IL1RL1 G 0.84 1.0x10-9 1.23 
[1.15-1.31] 
Asthma Ramasamy, PLoS 
One, 201227 
European 
2 rs10197862 102.97 IL1RL1 A/G 0.86 1.16 
[1.09-1.23] 
9.8x10-7 IL1RL1 A 0.85 4.0x10-11 1.24 
[1.16-1.32] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
2 rs3771166 102.99 IL18R1 A/G 0.35 0.89 
[0.86-0.93] 
5.0x10-8 IL18R1 G 0.62 3.0x10-9 1.15 
[1.10-1.20] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
3 rs9815663 3.61 . C/T 0.82 1 
[0.95-1.05] 
0.96 CRBN - LRRN1 T 0.182 2.0x10-8 0.84 
[NA] 
Childhood Asthma Forno, J Allergy 
Clin Immunol, 
201229 
European 
26 
    Meta-analysis of time-to-asthma onset 
GWASs 
GW results reported in GWAS for asthma and asthma-related traits 
NCBI GWAS Catalog, June 2015 
Chr SNP 
or proxy* 
Pos  
(Mb) 
Gene 
Symbol 
Effect/Ref 
Alleles† 
Effect 
Freq 
HR 
[95% CI] 
P‡ Mapped 
Genes 
Effect 
Allele 
Effect 
Freq 
in ctrls 
P OR 
[95% CI] 
Trait References Pop 
4 rs4833095 38.80 TLR1 C/T 0.27 0.95 
[0.9-0.99] 
0.02 TLR1 T 0.74 5.0x10-12 1.2 
[1.14-1.26] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
4 rs17218161 59.21 . NA NA NA NA SRIP1 - MIR548AG1 NA NA 2.0x10-8 NA Childhood Asthma Ding, Hum Genomics, 
201330 
European 
4 rs7686660 144.00 . G/T 0.24 0.99 
[0.94-1.03] 
0.50 FLJ44477 - USP38 T 0.27 2.0x10-12 1.16 
[1.11-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
4 rs3805236 144.36 GAB1 A/G 0.30 0.99 
[0.95-1.04] 
0.80 GAB1 G 0.25 7.0x10-8 1.20 
[1.14-1.26] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
5 rs1588265 59.37 . A/G 0.70 0.99 
[0.94-1.03] 
0.50 PDE4D C 0.29 3.0x10-8 1.18 
[1.08-1.30] 
Asthma Himes, Am J Hum 
Genet, 200932 
European 
5 rs1837253 110.40 . C/T 0.77 1.13 
[1.05-1.2] 
5.6x10-4 SLC25A46 - TSLP C 0.35 1.0x10-16 1.17 
[1.13-1.22] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
   . C/T 0.77 1.13 
[1.05-1.2] 
5.6x10-4 SLC25A46 - TSLP NA NA 1.0x10-14 NA Asthma Torgerson, Nat Genet, 
201125 
Multi-ethnic 
   . C/T 0.77 1.13 
[1.05-1.2] 
5.6x10-4 SLC25A46 - TSLP C 0.71 1.0x10-9 1.17 
[1.12-1.24] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
5 rs1438673 110.47 . C/T 0.54 1.08 4.5x10-5 WDR36 - RPS3AP21 C 0.49 3.0x10-11 1.16 Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
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    Meta-analysis of time-to-asthma onset 
GWASs 
GW results reported in GWAS for asthma and asthma-related traits 
NCBI GWAS Catalog, June 2015 
Chr SNP 
or proxy* 
Pos  
(Mb) 
Gene 
Symbol 
Effect/Ref 
Alleles† 
Effect 
Freq 
HR 
[95% CI] 
P‡ Mapped 
Genes 
Effect 
Allele 
Effect 
Freq 
in ctrls 
P OR 
[95% CI] 
Trait References Pop 
[1.04-1.13] [1.11-1.21] 
6 rs204993 32.16 PBX2 A/G 0.76 0.96 
[0.92-1.01] 
0.08 
 
PBX2 A 0.58 2.0x10-15 1.17 
[1.12-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs404860 32.18 NOTCH4 C/T 0.18 1 
[0.91-1.11] 
0.95 NOTCH4 A 0.5 4.0x10-23 1.21 
[1.16-1.25] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs3129943 32.34 C6orf10 A/G 0.75 1.01 
[0.97-1.06] 
0.62 C6orf10 T 0.62 3.0x10-15 1.17 
[1.12-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs3117098 32.36 . A/G 0.66 1.02 
[0.98-1.07] 
0.29 HNRNPA1P2 - 
BTNL2 
G 0.25 5.0x10-12 1.16 
[1.11-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs9268516 32.38 . C/T 0.68 0.93 
[0.87-0.99] 
0.02 BTNL2-HLA-DRA T 0.24 1.0x10-8 1.15 
[1.10-1.21] 
Asthma Ramasamy, PLoS 
One, 201227 
European 
6 rs3129890 
rs9268856* 
32.43 . A/C 0.22 0.97 
[0.92-1.01] 
0.15 HLA-DRA - HLA-
DRB9 
T 0.61 5.0x10-13 1.15 
[1.11-1.20] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs9272346 32.60 . A/G 0.61 1.13 
[1.08-1.17] 
1.6x10-8 HLA-DQA1 NA NA 2.0x10-8 NA Asthma Lasky-Su, Clin Exp 
Allergy, 201233 
European 
6 rs9273349 
rs9272346* 
32.60 . A/G 0.61 1.13 
[1.08-1.17] 
1.6x10-8 HLA-DQA1 - HLA-
DQB1 
C 0.58 7.0x10-14 1.18 
[1.13-1.24] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
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Freq 
in ctrls 
P OR 
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Trait References Pop 
6 rs9273373 32.63 . NA NA NA NA HLA-DQA1 - HLA-
DQB1 
G 0.54 4.0x10-14 1.24 
[1.17-1.30] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
6 rs7775228 32.66 . C/T 0.16 1.05 
[0.98-1.13] 
0.18 HLA-DQB1 - HLA-
DQA2 
A 0.63 5.0x10-15 1.17 
[1.12-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs9275698 32.69 . A/G 0.60 1.02 
[0.98-1.07] 
0.29 HLA-DQB1 - HLA-
DQA2 
T 0.79 5.0x10-12 1.18 
[1.12-1.24] 
Asthma Hirota, Nat Genet, 
201 31 
Japanese 
6 rs9500927 32.96 . A/G 0.16 1 
[0.95-1.05] 
0.98 BRD2 - HLA-DOA T 0.26 4.0x10-9 1.13 
[1.09-1.18] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
6 rs987870 33.04 . A/G 0.82 0.97 
[0.92-1.02] 
0.28 HLA-DPA1; HLA-
DPB1 
C 0.14 2.0x10-10 1.4 
[1.26-1.55] 
Asthma Noguchi, PLoS Genet, 
201134 
Japanese 
7 rs6967330 105.66 FLJ23834 A/G 0.18 1.13 
[1.07-1.19] 
1.4x10-5 CDHR3 A 0.19 3.0x10-14 1.26 
[1.18-1.33] 
Childhood Asthma Bonnelykke, Nat 
Genet, 201435 
European 
8 rs7009110 81.29 . C/T 0.59 0.93 
[0.9-0.97] 
7.6x10-4 RPS5P5 - ZBTB10 T 0.36 4.0x10-9 1.14 
[1.09-1.19] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
8 rs3019885 118.03 . G/T 0.48 1.02 
[0.98-1.06] 
0.40 SLC30A8 G 0.31 5.0x10-13 1.34 
[1.24-1.45] 
Asthma Noguchi, PLoS Genet, 
201134 
Japanese 
9 rs72699186 6.18 . NA NA NA NA RANBP6 - IL33 T 0.15 2.0x10-9 1.26 Asthma & hay fever Ferreira, J Allergy European 
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[1.16-1.35] Clin Immunol, 201428 
9 rs1342326 6.19 . A/C 0.79 0.84 
[0.8-0.88] 
1.6x10-12 RANBP6 - IL33 C 0.16 9.0x10-10 1.2 
[1.13-1.28] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
9 rs2381416 6.19 . A/C 0.68 0.85 
[0.81-0.89] 
3.6x10-14 RANBP6 - IL33 NA NA 2.0x10-12 NA Asthma Torgerson, Nat Genet, 
201125 
Multi-ethnic 
9 rs928413 6.21 . A/G 0.70 0.84 
[0.8-0.88] 
6.5x10-16 IL33 G 0.28 9.0x10-13 1.24 
[1.17-1.32] 
Childhood severe 
Asthma 
Bonnelykke, Nat 
Genet, 201435 
European 
9 rs16929097 12.52 . A/G 0.04 1.04 
[0.91-1.19] 
0.55 PTPRD - TYRP1 NA NA 8.0x10-9 NA Childhood Asthma Ding, Hum Genomics, 
201330 
European 
10 rs7915695 68.44 CTNNA3 NA NA NA NA CTNNA3 C 0.09 2.2x10-8 NA Asthma 
exacerbations 
McGeachie, J Allergy 
Clin Immunol,201536 
European 
10 rs12570188 100.86 HPSE2 NA NA NA NA HPSE2 NA NA 5.0x10-8 NA Childhood Asthma Ding, Hum Genomics, 
201330 
European 
10 rs10508372 8.97 . A/G 0.08 0.95 
[0.88-1.02] 
0.16 KRT8P16 - 
TCEB1P3 
C 0.433 2.0x10-15 1.16 
[1.12-1.21] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
11 rs7130588 76.27 . A/G 0.63 0.95 
[0.91-0.99] 
9.2x10-3 C11orf30 - LRRC32 G 0.34 2.0x10-8 1.09 
[1.06-1.13] 
Asthma Ferreira, Lancet, 
201124 
European 
11 rs215521 76.59  G/T 0.51 0.93 7.6x10-4 C11orf30 - LRRC32 T 0.48 5.0x10-11 1.16 Asthma & hay fever Ferreira, J Allergy European 
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[0.90-0.97] [1.11-1.21] Clin Immunol, 201428 
11 rs7927044 127.76 . A/G 0.01 1.09 
[0.89-1.33] 
0.43 NCRNA00288 - ETS1 A 0.0134 7.0x10-9 0.85 
[NA] 
Childhood Asthma Forno, J Allergy Clin 
Immunol, 201229 
European 
12 rs2069408 56.36 CDK2 A/G 0.66 0.98 
[0.94-1.02] 
0.31 CDK2 C 0.23 1.0x10-10 1.15 
[1.10-1.20] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
12 rs1701704 56.41 . G/T 0.35 1.03 
[0.99-1.08] 
0.10 SUOx - IKZF4 G 0.18 2.0x10-13 1.19 
[1.14-1.25] 
Asthma Hirota, Nat Genet, 
201131 
Japanese 
15 rs744910 67.45 SMAD3 A/G 0.49 0.93 
[0.9-0.97] 
3.2x10-4 SMAD3 G 0.49 4.0x10-9 1.12 
[1.09-1.16] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
15 rs17294280 67.47 SMAD3 A/G 0.71 0.93 
[0.88-0.98] 
4.9x10-3 SMAD3 G 0.23 4.0x10-9 1.18 
[1.11-1.25] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
16 rs62026376 11.23 CLEC16A NA NA NA NA CLEC16A C 0.72 1.0x10-8 1.17 
[1.11-1.24] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
17 rs2305480 38.06 GSDMB A/G 0.41 0.85 
[0.82-0.88] 
8.1x10-16 GSDMB G 0.60 6.0x10-23 1.32 
[1.23-1.39] 
Childhood severe 
Asthma 
Bonnelykke, Nat 
Genet, 201435 
European 
    A/G 0.41 0.85 
[0.82-0.88] 
8.1x10-16 GSDMB A 0.45  0.85 
[0.81-0.90] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
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17 rs11078927 38.06 GSDMB C/T 0.59 1.18 
[1.13-1.22] 
6.8x10-16 GSDMB NA NA 2.0x10-16 NA Asthma Torgerson, Nat Genet, 
201125 
Multi-ethnic 
17 rs7216389 38.07 GSDMB C/T 0.46 0.86 
[0.81-0.91] 
3.1x10-8 GSDMB T 0.52 9.0x10-11 1.45 
[1.17-1.81] 
Asthma Moffatt, Nature, 
200737 
European 
17 rs4794820 38.09 . A/G 0.40 0.86 
[0.82-0.89] 
1.0x10-13 ORMDL3 - GSDMA NA NA 1.0x10-8 1.33 
[1.20-1.45] 
Asthma Wan, Thorax, 201238 European 
17 rs3894194 38.12 GSDMA A/G 0.49 1.16 
[1.11-1.2] 
1.4x10-13 GSDMA A 0.45 5.0x10-9 1.17 
[1.11-1.23] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
    A/G 0.49 1.16 
[1.11-1.2] 
1.4x10-13 GSDMA A NA 3.0x10-21 1.59 
[1.44-1.76] 
Childhood severe 
Asthma 
Bonnelykke, Nat 
Genet, 201435 
European 
17 rs7212938 38.12 GSDMA G/T 0.50 1.18 
[1.13-1.23] 
1.1x10-15 GSDMA G 0.46 4.0x10-10 1.16 
[1.11-1.20] 
Asthma & hay fever Ferreira, J Allergy 
Clin Immunol, 201428 
European 
22 rs2284033 37.53 IL2RB A/G 0.41 0.94 
[0.9-0.98] 
2.1x10-3 IL2RB G 0.56 1.0x10-8 1.12 
[1.08-1.16] 
Asthma Moffatt, N Engl J 
Med, 20101 
European 
* The SNP with the strongest LD with the reported SNP in the literature was used if the SNP reported in the literature was not available in the imputed data 358 
†For the calculation of the hazard and odds ratios, Effect alleles (Effect) were designated as risk alleles. Effect Freq denotes frequency of the effect allele, CI confidence 359 
interval, and Ref reference allele 360 
32 
‡P-values are shown for tests of association under a fixed-effect model when there was no significant evidence of heterogeneity or under a random-effect model otherwise. 361 
Associations with P-values ≤ 0.001 in the time-to-asthma onset meta-analysis are indicated in bold 362 
NA: Not available363 
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FIGURE LEGENDS 364 
Figure E1. Distribution of age-of-asthma onset 365 
Figure E2. Quantile-quantile (QQ) plots of 2,387,926 SNPs of nine GWAS (N = 13,886) 366 
after quality control (Rsq≥0.50, MAF≥0.01, ≥6 contributing studies) under a fixed-effect 367 
model (inflation factor, λGC=1.04). The dots represent the distribution of observed Chi-Square 368 
values against the theoretical model distribution of expected Chi-Square values. The red line 369 
represents the theoretical model distribution of expected Chi-Square values under the null 370 
distribution. 371 
Figure E3. Regional association plots of the genome-wide associated regions using 372 
Locuszoom39 software: 2q12, 6p21, 9p24, 17q12-q21. SNPs are plotted with their P-values (-373 
log10 values, left y-axis) as a function of genomic position (x-axis). Estimated recombination 374 
rates (right y-axis) taken from 1000 Genomes (March 2012 EUR) are plotted in cyan to reflect 375 
the local LD structure. SNPs surrounding the most significant SNP (purple circle) are color-376 
coded according to LD with lead SNP (pairwise r2, according to a blue to red scale from r²=0 377 
to 1). In 9p24 and 17q12-q21 regions, additional SNP detected by conditional analyses is 378 
indicated by an arrow (Part A). Two additional plots show SNPs color-coded according to LD 379 
with additional SNP detected in conditional analysis (Part B). 380 
Figure E4. Forest plots of hazard ratios for SNPs associated with time-to-asthma onset at 381 
genome-wide significant level (P≤5x10-8) and two additional SNPs detected by conditional 382 
analyses in 9p24 and 17q12-q21 regions. The hazard ratios and 95% confidence intervals for 383 
seven loci show distinct effect on time-to-asthma onset. In each plot, the diamond indicates 384 
the effect size and the 95% CI derived from the meta-analysis of nine studies. 385 
Figure E5. Regional plots of 9p24 (Part-a) and 17q12-q21 (Part-b) regions for distinct 386 
association signals using sequential conditional analysis and time-to-asthma onset as an 387 
outcome variable: original meta-analysis (A), adjusted for lead SNP (B) and additionally 388 
34 
adjusted for the secondary signal (C). Signals above the red line (P<10−5) were considered to 389 
exhibit evidence of association in the regions. SNPs are colored according to their pairwise 390 
LD r² with the lead SNP. r² was estimated from 1000 Genomes (March 2012 EUR). 391 
Figure E6. Association plots of the fine-mapping conducted in 16q12 region using 1000G 392 
CEU reference sample. SNPs are plotted with their P-values (-log10 values, left y-axis) as a 393 
function of genomic position (x-axis). Estimated recombination rates (right y-axis) taken from 394 
1000G are plotted to reflect the local LD structure around the top associated SNP (purple 395 
circle) and correlated proxies (according to a blue to red scale from r² = 0 to 1). 396 
 397 
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